What is Innoviva Inc's share price today?
Innoviva Inc (INVA) share price today is $21.29 as of October 30, 2026 at 1:30 AM IST. The stock touched a day high of $21.43 and a day low of $21.11.What exchange does Innoviva Inc stock trade on, and under what ticker symbol?
Innoviva Inc stock trades on NASDAQ under the ticker symbol INVA.What is Innoviva Inc's market capitalization?
Innoviva Inc's market capitalization is $1.51B as of October 30, 2026 at 1:30 AM IST.What is Innoviva Inc's price-to-earnings (P/E) ratio?
Innoviva Inc's price-to-earnings (P/E) ratio is 4.89 as of October 29, 2026.What is Innoviva Inc's price-to-book (P/B) ratio?
Innoviva Inc's price-to-book (P/B) ratio is 1.23 as of October 29, 2026.Can Indian investors buy Innoviva Inc shares?
Yes, You can buy Innoviva Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Innoviva Inc shares from India?
Indian investors can buy Innoviva Inc shares in three steps: 1. Search Innoviva Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Innoviva Inc shares for Indian investors?
Since Innoviva Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Innoviva Inc shares via Tickertape?
Indian investors can start investing in Innoviva Inc (INVA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4696 shares at the current price of $21.29.
$
₹
$21.290.82% (+0.17)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
4.89
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
1.23
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$4.28
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
3.14
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
81.19%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 5 analysts reports
Buy4 analysts
Hold0 analyst
Sell1 analyst
Price Upside
+64.24%
Earnings Growth
-26.78%
Rev. Growth
+6.15%
Company Profile
Company Profile
P/E Ratio
42.94
42.94
1Y Return
69.1%
69.1%
Buy Reco %
83.87
83.87
P/E Ratio
40.77
40.77
1Y Return
48.41%
48.41%
Buy Reco %
69.56
69.56
P/E Ratio
112.55
112.55
1Y Return
69.01%
69.01%
Buy Reco %
70.37
70.37
P/E Ratio
29.93
29.93
1Y Return
32.26%
32.26%
Buy Reco %
41.66
41.66
P/E Ratio
25.42
25.42
1Y Return
3.56%
3.56%
Buy Reco %
83.33
83.33
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$21.31Baseline
Analyst Target - 1 year
Target$35+64.24%
All values in $
2026
Current$21.31Baseline
Analyst Target - 1 year
Target$35+64.24%
All values in $
Revenue Forecast
Revenue Forecast
Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 6.15% growth, versus a trailing 3-year CAGR of 8.66%.
2025
Current$425.12Baseline
Forecast for Dec 2026
High$491.8+15.68%
Average$451.29+6.15%
Low$421.5-0.85%
All values in $ Million
2025
Current$425.12Baseline
Forecast for Dec 2026
High$491.8+15.68%
Average$451.29+6.15%
Low$421.5-0.85%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies -26.78% growth, versus a trailing 3-year CAGR of 70.09%.
2025
Current$3.05Baseline
Forecast for Dec 2026
High$2.56-16.1%
Average$2.23-26.78%
Low$1.49-51.17%
All values in $
2025
Current$3.05Baseline
Forecast for Dec 2026
High$2.56-16.1%
Average$2.23-26.78%
Low$1.49-51.17%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 77.49 | 103.35 | 89.50 | 91.80 | 88.63 | 100.28 | 107.8 | 118.04 | 97.99 | 119.59 |
Gross Profit | 66.52 | 84.96 | 79.51 | 84.64 | 79.79 | 89.69 | 82.02 | 75.61 | 75.83 | 90.61 |
| Net Income | 36.53 | -34.68 | 1.21 | 20.33 | -46.58 | 63.68 | 89.90 | 164.15 | 186.59 | -83.42 |
| Net Profit Margin | 47.13% | -33.55% | 1.35% | 22.14% | -52.55% | 63.50% | 83.40% | 139.05% | 190.41% | -69.75% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Innoviva Inc | 4.89 | 1.23 | 3.14 |
| Eli Lilly and Company | 42.94 | 33.65 | 1.22 |
| Johnson & Johnson | 40.77 | 7.86 | 2.99 |
Price Comparison
Price Comparison
Compare INVA with any stock or ETFCompare INVA with any stock or ETF
Comparing from
INVA
LLY
JNJ
The 12-month consensus target implies 64.24% growth, versus a trailing 3-year CAGR of 19.72%.